EDGAR Filing Documents for 0001104659-20-084106

Form 4 - Statement of changes in beneficial ownership of securities:

SEC Accession No. 0001104659-20-084106

Filing Date

2020-07-16

Accepted

2020-07-16 16:53:14

Documents

Period of Report

2020-07-14

Document Format Files

Seq	Description	Document	Type	Size
1	4	a4.html	4
1	4	a4.xml	4	7159
	Complete submission text file	0001104659-20-084106.txt		9281

Mailing Address LICHTSTRASSE 35 CH-4002 BASEL V8

Business Address LICHTSTRASSE 35 CH-4002 BASEL V8 212-830-2474

NOVARTIS PHARMA AG (Reporting) CIK: 0001030617 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39376 | Film No.: 201031918

Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056

Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111

NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39376 | Film No.: 201031919
SIC: 2834 Pharmaceutical Preparations

Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121

Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100

Poseida Therapeutics, Inc. (Issuer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)